Avandia Lawsuit Filed by 8 in Texas

A group of Texas plaintiffs have added to the pile of <"http://www.yourlawyer.com/topics/overview/avandia">Avandia lawsuits heading to court. The 8 individuals filed suit against GlaxoSmithKline alleging Avandia caused them to suffer various heart problems, and are seeking a full refund for their purchases of the type 2 diabetes drug.

Avandia belongs to a class of diabetes drugs called thiazolidinediones that lower blood sugar by decreasing insulin resistance. Since November 2007, Avandia’s U.S. label has included a black box warning detailing its association with heart attacks. The black box was added after Dr. Steven Nissen of the Cleveland Clinic published a study showing that patients taking Avandia had a 40 percent increase in the risk of cardiovascular disease. Since 2007, more evidence of Avandia’s heart risks has accumulated.

Last year, the U.S. Food & Drug Administration (FDA) placed severe restrictions on sales of Avandia, after determining its heart risks outweighed its benefits. Actos has been pulled from retail pharmacies, and is only be available to patients who are already taking it and whose diabetes cannot be controlled with any other medication, or those who do not wish to take an alternative drug called Actos.

According to the Southeast Texas Record, this latest lawsuit alleges Avandia is a defective product because it put the patients at too high a risk for suffering heart attacks. The lawsuit accuses Glaxo of, among other things, negligence, fraud, unjust enrichment, violation of Deceptive Trade Practices Act and gross negligence.

In addition to a full refund of their Avandia purchases, the plaintiffs are seeking compensation for physical pain, mental suffering, physical impairment, current and future medical expenses and other damages.

Though it was once the best selling diabetes drug in the world (1 million Americans were taking it by 2006), Avandia sales declined sharply once its association with heart problems was revealed. According to the FDA, as of last October, only 119,000 U.S. patients were taking Avandia.

This entry was posted in Avandia, Pharmaceuticals. Bookmark the permalink.

© 2005-2020 Parker Waichman LLP ®. All Rights Reserved.